Digital therapy: reimbursement does not create adoption

An app can be recognised as a medical device, address a specific indication and remain absent from everyday clinical work. That gap is commercial, operational and clinical at once. On 1 July 2026, compulsory health insurance began covering an interactive digital cognitive behavioural therapy application for certain forms of depression. Prescribing is restricted to specified professionals, use is limited to 90 days and the item is under evaluation until the end of 2026. A reimbursement code opens a door; it does not train prescribers, organise patient information or show that the therapy suits every situation. This insight follows regulatory eligibility, medical decision, activation and follow-up . It identifies a first purchase: a prescriber-activation study in one territory, paired with a practice integration protocol. It explains how to measure adoption without turning depression into an advertising segment or promising a therapeutic outcome. Potential exists because eligible prescribers are identifiable; its value depends on cautious implementation, support and separate evidence at every stage. General analysis updated on 7 August 2026. It does not replace a prescription, clinical judgement, reimbursement decision or surveillance decision.

Since 1 July 2026, compulsory health insurance may cover an interactive digital cognitive behavioural therapy application for defined forms of depression. The licence lasts no more than 90 days, and prescribing is restricted to the specialists and qualifications specified in the MiGeL list. The item is under evaluation until 31 December 2026.

The Federal Office of Public Health states that the application is used to complement psychotherapy or while a patient is waiting for a consultation. It must meet the tariff item's conditions, including those concerning effectiveness, appropriateness and use. This is neither a generic wellbeing app nor an automatic replacement for a therapeutic relationship.

Reimbursement alone is insufficient because the prescriber must know the tool, confirm the indication, explain its role and respond if the patient does not activate it or the clinical situation changes. A practice has to add a new decision to limited consultation time. Without a simple pathway, financial access remains separate from use.

The supplier must answer practical questions about available languages, support, data protection, access difficulties and the connection with the next appointment. Commercial communication must never bypass medical judgement. Its role is to give professionals the information they need to make their own decision.

The first practical purchase is an activation study for one territory or network: eligible prescriber audience, current pathway, objections, documentation, support and capacity. It ends with a bounded pilot plan for a small group of practices and stage-specific indicators. It promises neither prescriptions, individual reimbursement nor clinical improvement.

The partner chooses an area where the supplier can provide support and process feedback. It conducts professional interviews, reviews documents and confirms that prescriptions use an unambiguous product designation. The parties agree the fee, duration and number of practices before acquisition begins. Clinical or regulatory questions beyond the commercial team's competence go to the designated accountable specialist.

Prescribers are identified from professional sources by specialty, role and territory. The campaign uses no diagnosis, patient list or individual health behaviour. Outreach offers information about the prescribing pathway; only the healthcare professional decides whether the tool is appropriate for a particular person.

Associations, congresses, care networks and specialist content can support awareness. Search content addresses questions about reimbursement. Direct contact becomes useful once the professional role is confirmed. Every channel must comply with the rules governing advertising for therapeutic products and with the supplier's internal approval process.

A defensible message separates medical-device status, reimbursement conditions, clinical evidence and practical use. It states the indication and limitations precisely. An efficacy study does not guarantee an individual's outcome; a MiGeL item does not endorse every product feature; adoption does not establish adherence throughout the 90-day period.

How to read the diagram. Acquisition ends with the professional; the clinical decision starts there.

Integration should provide a short briefing sheet, a prescribing procedure, patient support and a follow-up rule. The practice should not have to reconstruct instructions for each case. The supplier tests the journey with professional users, measures the time required and fixes friction before widening the campaign.

Administrative staff may prepare some elements, but medical judgement remains with the prescriber. Incidents, difficulties and discontinuations follow a known procedure. The supplier must specify which data it receives and which information remains in the professional's clinical record.

Past the midpoint of this insight, the Healthcare and practices market page links this activation challenge with TARDOC, medical admission and KVG quality. The initial purchase remains distinct: it does not recode a consultation or select a canton; it makes a reimbursable tool usable by authorised prescribers.

Indicators should track four stages: informed professional, qualified appointment, compliant prescription and activation, followed by use where authorised data permits. Every stage has a different denominator. Combining downloads, prescriptions and treatments hides friction. Clinical outcomes belong to medical evaluation and must not become an improvised advertising measure.

Before the pilot, the supplier and partner define which events can be measured without collecting excessive data. Figures remain confidential. Any illustrative demonstration is clearly marked as a scenario and never presented as observed performance.

The relationship can recur when new practices, territories or indications require activation, or when support and training form a distinct service. A 90-day patient licence describes insurance coverage, not automatic consultancy revenue. Every commercial cycle must relate to a paid service and real delivery capacity.

The FOPH establishes the effective date, MiGeL item, eligible prescribers and evaluation period; the Health Insurance Benefits Ordinance and KVG govern coverage; Swissmedic regulates the medical device. These sources recommend no product to an individual and guarantee neither a prescription, reimbursement in a particular case nor a therapeutic outcome.

Official references and verification dates remain in the private source file. This public insight names the authorities without external links. The supplier must revalidate the item and its status before every campaign, particularly after the evaluation period ends.

The complimentary eligibility assessment reviews your status, evidence, prescriber pathway, acquisition challenge and support capacity. It makes no therapeutic recommendation. It establishes whether getfishnet and your team could build a tailored strategy around reimbursed access, a professional audience and a measurable pilot.